Wegovy Weight Loss Data 2026 released at the European Congress on Obesity (ECO) in Istanbul, Türkiye, has sent waves through the medical community. Novo Nordisk announced today that new sub-analyses from its landmark STEP UP clinical trial demonstrate that patients identified as “early responders” achieved a staggering 27.7% mean weight loss after 72 weeks of treatment with a 7.2 mg dose of semaglutide.
Key Highlights of Wegovy Weight Loss Data 2026
The data highlights a significant breakthrough in personalized obesity care. Early responders, defined as individuals who lost at least 15% of their body weight within the first 24 weeks, showed the most profound long-term benefits. This group represented approximately 1 in 4 participants (27%) on the higher 7.2 mg dose, compared to 21% on the standard 2.4 mg dose.
Beyond total weight loss, the study utilized advanced MRI scanning to evaluate body composition. The results indicated that 84% of the weight lost was specifically from fat mass, while muscle function remained remarkably preserved. This addresses a major concern in weight management: the potential loss of lean muscle during rapid weight reduction.
Understanding the STEP UP Trial Methodology
The STEP UP trial involved over 1,400 adults living with obesity without type 2 diabetes. Participants were randomized to receive either the high-dose 7.2 mg injection, the 2.4 mg injection, or a placebo over a 72-week period.
According to Novo Nordisk’s official press release, the higher dose allowed patients to reach their weight loss goals significantly faster than those on lower doses. This efficiency is expected to improve patient adherence and long-term outcomes.
Impact on Obesity Care and Global Health
Emil Kongshøj Larsen, executive vice president at Novo Nordisk, stated that these findings underscore the potential of the higher-dose portfolio to “achieve substantial weight loss” while ensuring that “muscle function is preserved.” This is critical for patients who require not just a lower number on the scale, but an improvement in overall metabolic and cardiometabolic health.
Wegovy Weight Loss Data 2026: Financial and Market Context
The clinical success comes on the heels of Novo Nordisk’s Q1 2026 financial results, which showed a 22% increase in adjusted Obesity care sales. Despite pricing pressures in the US market, the rapid adoption of the Wegovy® pill and the high-dose injection variant continues to drive the company’s upgraded 2026 outlook.
STEP UP Trial Weight Loss Outcomes (72 Weeks)
| Metric | Wegovy 7.2 mg | Wegovy 2.4 mg | Placebo |
| Mean Weight Loss (%) | 21.0% | 17.5% | 2.4% |
| Mean Weight Loss (kg) | ~23 kg | ~19.8 kg | ~2.7 kg |
| Early Responders (%) | 27.0% | 21.0% | 3.0% |
| Early Responders Weight Loss | 27.7% | N/A | N/A |
| Fat Mass Reduction (%) | 84% of total loss | 84% of total loss | N/A |
| Visceral Fat Reduction | >30% | >30% | N/A |
Novo Nordisk Q1 2026 Financial Summary (DKK Million)
| Financial Category | Reported Q1 2026 | Adjusted Q1 2026 | Growth (CER) |
| Total Net Sales | 96,823 | 70,063 | -4% (Adj) / +32% (Rep) |
| Obesity Care Sales | 23,343 | 23,343 | +27% |
| Operating Profit | 59,618 | 32,858 | -6% (Adj) / +65% (Rep) |
| US Operations Sales | 62,145 | N/A | -11% (Adj) |
| International Sales | 34,678 | 34,678 | +6% |
Wegovy Weight Loss Data 2026 – Women’s Health Sub-analysis
| Life Stage | Heart Attack/Stroke Risk Reduction | Key Quality of Life Benefit |
| Premenopausal | Consistent with SELECT Trial | 42-45% lower migraine risk |
| Perimenopausal | 42% Risk Reduction | 25% lower depression risk |
| Postmenopausal | 13% Risk Reduction | Improved body composition |
